AliveCor QT Service vs Cleerly ISCHEMIA
AI Verdict
Choose AliveCor QT Service if…
Choose AliveCor QT Service if you need immediate, accurate assessment of QT and QTc intervals from ambulatory ECGs to evaluate cardiac safety, particularly when managing patients on or considering QT-prolonging medications. This tool is ideal for rapid screening and ongoing monitoring to inform medication prescribing decisions and mitigate the risk of drug-induced arrhythmias.
View AliveCor QT Service →Choose Cleerly ISCHEMIA if…
Choose Cleerly ISCHEMIA if you require a non-invasive, AI-powered analysis of CCTA scans to determine the likelihood of coronary artery ischemia at a vessel level. This tool is best suited for physicians seeking detailed insights into coronary plaque characteristics, stenosis severity, and functional significance to personalize diagnosis and treatment planning for heart disease.
View Cleerly ISCHEMIA →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AliveCor QT Service | Cleerly ISCHEMIA |
|---|---|---|
| Pricing | Varies by product and service, with subscription options available. | Unknown |
| Deployment | Mobile app, cloud-based platform, EHR integration. | Web-based solution |
| BAA Available | Yes AI-estimated | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AliveCor QT ServiceTool A offers superior usability due to its integration with the portable KardiaMobile 6L device, enabling quick, point-of-care ECG measurements that can be self-administered by patients after simple instructions. This streamlined workflow and reported ease of use by healthcare professionals enhance efficiency in diverse clinical settings.
Clinical Value
Cleerly ISCHEMIATool B provides superior clinical value through its comprehensive, AI-driven assessment of coronary artery disease, including non-invasive FFR estimation, detailed plaque characterization, and stenosis severity from CCTA scans. Its robust clinical validation in multiple trials demonstrates higher diagnostic accuracy and prognostic utility for major adverse cardiovascular events.
Pricing & Value
TieBoth tools lack transparent, publicly available pricing information, requiring direct contact with the vendor for details. While Tool B is billable under a Category I CPT code, indicating established reimbursement, specific costs to the end-user or institution are not disclosed for either product.
Enterprise Readiness
AliveCor QT ServiceTool A demonstrates a slight edge in enterprise readiness by explicitly listing a broader range of API integration targets, including EHR, SDK, CRM, EDC, and PSP platforms. This suggests greater versatility and adaptability for seamless integration into diverse healthcare IT ecosystems.
Innovation
Cleerly ISCHEMIATool B exhibits greater innovation by offering AI-enabled CCTA analysis for non-invasive fractional flow reserve (FFR) estimation and comprehensive coronary plaque characterization with 3D models. This significantly advances non-invasive diagnostics for heart disease, providing detailed, actionable insights that previously required more invasive methods.
Support & Docs
TieNeither tool provides specific details on service level agreements, guaranteed response times, or comprehensive public knowledge bases that would allow for a clear differentiation. Both companies indicate a commitment to customer support and offer various resources such as publications and webinars.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AliveCor QT Service | Cleerly ISCHEMIA |
|---|---|---|
| Name | AliveCor QT Service | Cleerly ISCHEMIA |
| Company | AliveCor | Cleerly |
| Primary Purpose | Provides instant, accurate QT and QTc interval measurements from AliveCor 6-Lead ECGs to assess cardiac safety and inform medication prescribing decisions. | Analyzes CCTA scans to non-invasively determine the likelihood of coronary artery ischemia at a vessel level, aiding physicians in personalized diagnosis and treatment planning for heart disease. |
| Input Data Type | AliveCor 6-Lead ECGs | CCTA scans |
| Key Measurement/Analysis | Measures QT and QTc intervals (Bazett's and Fridericia's formulas), utilizes AI and deep neural networks for ECG analysis. | Non-invasive fractional flow reserve (FFR) estimation, vessel-level ischemia likelihood determination, coronary plaque characterization (volume, type, location), stenosis severity assessment. |
Videos
Demos, reviews, and walkthroughs featuring AliveCor QT Service and Cleerly ISCHEMIA.
Frequently Asked Questions
More Comparisons
More matchups featuring AliveCor QT Service or Cleerly ISCHEMIA
Backers
Who funded each tool's parent company.